Diabetic retinopathy (DR) remains a leading cause of vision loss among working-age adults, affecting nearly one in three people with diabetes. While well-known risk factors such as poor blood sugar control, high blood pressure, and abnormal cholesterol levels dominate clinical attention, a growing body of research highlights another endocrine contributor: hyperthyroidism. This condition, characterized by overproduction of thyroid hormones, not only disrupts whole-body metabolism but also appears to accelerate the retinal vascular damage typical of diabetes. Recognizing and managing this connection is essential for clinicians seeking to preserve vision through comprehensive, integrated care. The prevalence of hyperthyroidism in the diabetic population is estimated at 5–10%, yet systematic screening remains inconsistent, leaving a substantial number of patients at increased risk for accelerated retinopathy progression.

How Hyperthyroidism Harms the Retina

Systemic Effects of Excess Thyroid Hormones

Hyperthyroidism—most often caused by Graves’ disease, toxic nodular goiter, or thyroiditis—leads to elevated levels of triiodothyronine (T₃) and thyroxine (T₄). These hormones increase the basal metabolic rate, cardiac output, and oxygen consumption. In blood vessels, they stimulate endothelial nitric oxide synthase, causing widespread vasodilation. For a retina already compromised by diabetic microvascular disease, the resulting increase in blood flow imposes harmful shear stress on weakened capillaries, promoting leakage and rupture. This hemodynamic insult is compounded by the direct effects of thyroid hormones on retinal cells, mediated through nuclear thyroid hormone receptors (THRs) expressed in retinal endothelial cells, pericytes, and Müller glia. Activation of THRα and THRβ alters gene transcription, influencing vascular tone, proliferation, and survival pathways.

Fueling Inflammation and Oxidative Stress

Excess thyroid hormones create a pro-inflammatory environment. Studies consistently show elevated tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein in hyperthyroid patients. These inflammatory mediators disrupt the blood-retinal barrier, allowing fluid and inflammatory cells to infiltrate the retinal tissue. At the same time, heightened oxidative stress—driven by accelerated mitochondrial activity and increased production of reactive oxygen species (ROS)—damages endothelial cells and pericytes, the cells that support retinal capillaries. This combined inflammatory and oxidative attack accelerates the transition from non-proliferative diabetic retinopathy (NPDR) to the more dangerous proliferative diabetic retinopathy (PDR). Additionally, thyroid hormones upregulate NADPH oxidase enzymes, further amplifying ROS generation and creating a vicious cycle of vascular injury.

Angiogenic Imbalance

Vascular endothelial growth factor (VEGF) is the primary driver of abnormal blood vessel growth in PDR. Thyroid hormones can directly upregulate VEGF expression through response elements in the VEGF gene promoter and indirectly by stabilizing hypoxia-inducible factor-1 alpha (HIF-1α). In a hyperthyroid state, even mild retinal ischemia triggers a robust VEGF response, leading to the growth of fragile, leaky new vessels. Another pro-angiogenic factor, angiopoietin-2, is also elevated, further destabilizing existing retinal capillaries and creating a landscape ripe for vision-threatening complications. Beyond VEGF, hyperthyroidism increases levels of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF), which promote pericyte recruitment and fibrosis, respectively. This multifaceted angiogenic drive means that anti-VEGF therapy alone may be insufficient in hyperthyroid patients, as alternative pathways can sustain neovascularization.

Population Studies

A major prospective cohort study by Kim and colleagues (2021) followed nearly 5,000 adults with type 2 diabetes for a median of 7.8 years. Those with newly diagnosed hyperthyroidism had a 1.9-fold higher risk (HR 1.93, 95% CI 1.34–2.78) of progressing to vision-threatening DR, even after adjusting for HbA1c, blood pressure, and lipid levels. A later case-control analysis using Taiwan’s National Health Insurance Research Database confirmed this pattern, showing that people with hyperthyroidism had 42% higher odds of developing DR over a decade. A meta-analysis of six studies published in 2023 reported a pooled odds ratio of 1.71 (95% CI 1.42–2.06) for DR progression in patients with hyperthyroidism compared to euthyroid controls, with higher effect sizes in studies that included both type 1 and type 2 diabetes. The consistency across diverse populations and study designs strengthens the case for a causal relationship.

Imaging Evidence

Optical coherence tomography angiography (OCTA) studies reveal that diabetic patients with coexisting hyperthyroidism have significantly larger foveal avascular zones (FAZ) and reduced capillary perfusion density in the deep retinal plexus compared to diabetic patients with normal thyroid function. These microvascular changes are directly linked to the development of diabetic macular edema (DME) and subsequent vision loss. Newer imaging modalities, such as adaptive optics scanning laser ophthalmoscopy, have shown that hyperthyroid patients also exhibit increased venous tortuosity and arteriolar narrowing, suggesting a generalized microangiopathic burden. These structural abnormalities correlate with reduced retinal sensitivity on microperimetry testing, even before clinically detectable DR, highlighting the insidious nature of the synergistic damage.

The Timing of Thyroid Dysfunction

Interestingly, the harmful effect of hyperthyroidism appears strongest when it occurs early in the course of diabetes. A subanalysis of the ACCORD Eye Study found that participants with hyperthyroidism at baseline had a 2.3-fold higher incidence of DR development over 4 years. Those who developed hyperthyroidism later showed less dramatic progression, likely because advanced glycation end-products and irreversible capillary dropout had already reduced the retina’s ability to respond to the added vascular stress. This temporal relationship suggests that early detection and treatment of hyperthyroidism may yield the greatest benefit in preserving retinal health. Experimental models confirm that thyroid hormone exposure during early stages of diabetic microvascular disease leads to more pronounced pericyte loss and capillary non-perfusion.

The Bidirectional Relationship: Does Diabetic Retinopathy Affect Thyroid Function?

While the focus has been on hyperthyroidism worsening DR, emerging evidence hints at a bidirectional interaction. Chronic inflammation and oxidative stress from DR may influence the hypothalamic-pituitary-thyroid axis, potentially triggering autoimmune thyroid disease in susceptible individuals. Some small studies have reported higher anti-thyroid peroxidase (anti-TPO) antibody levels in patients with proliferative DR compared to those without retinopathy, suggesting that shared autoimmune mechanisms may underlie both conditions. However, large-scale prospective studies are needed to clarify this relationship. For now, clinicians should remain aware that DR and thyroid dysfunction may reinforce each other through common inflammatory pathways.

Integrating Thyroid Screening into Eye Care

When to Screen

Current American Diabetes Association guidelines recommend annual dilated eye exams for patients with type 2 diabetes at diagnosis and for those with type 1 diabetes after five years. However, thyroid function testing (TSH, free T₄, and sometimes T₃) is not routine unless symptoms of thyroid disease are present. Given the accumulating evidence, a targeted screening approach is warranted:

  • At initial diagnosis of diabetic retinopathy—especially if moderate NPDR or worse is identified.
  • In patients with unexplained rapid progression despite stable glycemic control.
  • Presence of clinical signs of hyperthyroidism, such as unexplained weight loss, tachycardia, tremor, or heat intolerance.
  • In women of childbearing age, where both hyperthyroidism and DR can accelerate during pregnancy.
  • Before intensive diabetes therapy initiation, as rapid glycemic improvement can paradoxically worsen DR, and coexisting hyperthyroidism may potentiate this risk.

Laboratory Evaluation

Initial screening should include serum thyroid-stimulating hormone (TSH). A suppressed TSH (<0.5 mIU/L) warrants measurement of free T₄ and total or free T₃ to confirm overt hyperthyroidism. Even subclinical hyperthyroidism (low TSH with normal free T₄ and T₃) has been linked to increased cardiovascular risk and may merit investigation in diabetic patients. In cases of suspected Graves’ disease, additional tests such as thyroid-stimulating immunoglobulin (TSI) and thyroid ultrasound can help establish the etiology. For patients with central obesity or insulin resistance, consider that TSH may be artefactually low due to sick euthyroid syndrome; free thyroid hormone levels should guide decision-making in such scenarios.

Managing Both Conditions Together

Restoring Normal Thyroid Function

The primary goal is to achieve and maintain a euthyroid state. Treatment options include:

  • Antithyroid medications—methimazole (preferred due to lower hepatotoxicity) or propylthiouracil (used in early pregnancy). These drugs inhibit thyroid peroxidase and reduce hormone synthesis. Methimazole also has mild anti-inflammatory properties that may benefit retinal vascular health.
  • Radioactive iodine therapy—a definitive treatment that destroys thyroid follicular cells, usually leading to hypothyroidism within 6–12 weeks, followed by levothyroxine replacement. This approach may be less suitable for patients with active DR because of the abrupt hormonal shift.
  • Thyroidectomy—reserved for large goiters, compressive symptoms, or when medical therapy fails. Total thyroidectomy removes all thyroid tissue, resulting in immediate hypothyroidism that can be managed with replacement. The surgical approach avoids radiation exposure but carries its own risks.

Importantly, rapid correction of hyperthyroidism—especially with radioiodine—can transiently worsen retinopathy due to abrupt changes in vascular tone and cytokine release. A gradual normalization over weeks using antithyroid medications is often safer. During the transition to euthyroidism, close ophthalmologic monitoring every 4–6 weeks is advisable.

Optimizing Diabetes Control

Meticulous blood glucose and blood pressure management is essential. Hyperthyroidism increases insulin clearance and can worsen insulin resistance. Metformin, SGLT-2 inhibitors, and GLP-1 receptor agonists offer favorable effects on both glucose control and retinal outcomes. Clinicians must be cautious with sulfonylureas and insulin, as dose requirements may fluctuate during thyroid treatment. After thyroid function normalizes, insulin clearance decreases, and doses may need to be reduced to avoid hypoglycemia. Blood pressure targets should be stricter, aiming for <130/80 mmHg, as hyperthyroidism-induced tachycardia and increased pulse pressure further stress retinal vessels.

Intravitreal Therapies

For patients who develop DME or PDR, anti-VEGF injections (e.g., ranibizumab, aflibercept) remain the cornerstone of treatment. However, hyperthyroidism may require more frequent injections due to enhanced VEGF release. A small retrospective series reported a mean of 8.1 injections over 12 months in hyperthyroid patients compared to 5.6 in euthyroid controls (p=0.003). Adjusting treatment expectations and follow-up intervals is important in these complex cases. In patients who respond poorly to anti-VEGF therapy despite adequate thyroid control, switching to a dual-mechanism agent such as faricimab (targeting VEGF-A and angiopoietin-2) may offer additional benefit, as it simultaneously addresses two of the key angiogenic pathways upregulated in hyperthyroidism.

Special Populations: Pregnancy and Children

Pregnancy

Pregnancy itself increases insulin resistance and retinal blood flow. When hyperthyroidism is superimposed—most commonly from gestational Graves’ disease—the risk of DR progression rises sharply. The Danish National Birth Cohort reported a 3.5-fold increased odds of developing severe PDR during pregnancy in women with untreated hyperthyroidism. All pregnant diabetic patients with hyperthyroidism should undergo monthly dilated eye exams, and management should involve a multidisciplinary team. Propylthiouracil is the preferred antithyroid drug during the first trimester due to methimazole’s teratogenic potential. After delivery, thyroid disease often remits, but retinal changes may persist. Postpartum follow-up should include OCTA at 3 and 6 months to assess for residual macular edema.

Children and Adolescents

Pediatric DR is uncommon before puberty, but hyperthyroidism can accelerate its onset. A study of 128 adolescents with type 1 diabetes found that those with hyperthyroidism (often part of autoimmune polyglandular syndrome) had significantly higher rates of pre-proliferative DR by age 18. Early thyroid screening and aggressive treatment of both conditions are recommended in pediatric diabetics with a family history of autoimmune endocrine disorders. The impact of thyroid hormone on retinal development is still being investigated; animal models suggest T₃ influences the timing of retinal vascular maturation, potentially making the young retina more susceptible to diabetic damage.

The Elderly

In older adults, hyperthyroidism often presents with atypical symptoms such as atrial fibrillation, weight loss, or cognitive decline, and may be overlooked. Diabetic elderly patients with unexplained visual deterioration should undergo TSH testing. Treatment with antithyroid drugs rather than definitive therapy is often preferred to avoid the risk of treatment-induced hypothyroidism and its effects on cognition and bone health. The threshold for initiating diabetic retinopathy treatment may need to be lower in this group, as coexisting age-related macular degeneration can complicate the clinical picture.

Future Directions and Research Gaps

While the epidemiological link is strong, several questions remain. The effect of hyperthyroidism on other retinal cell types—such as retinal ganglion cells and Müller glia—is being studied in animal models. The role of thyroid hormone receptor beta (TRβ) agonists, currently explored for metabolic diseases, could theoretically be repurposed to block the pro-angiogenic effects of T₃ at the retinal level without affecting systemic thyroid status. Early phase trials are evaluating topical thyroid hormone antagonists for DME, with promising results in reducing central macular thickness.

Another promising avenue is the use of biomarkers. Plasma levels of soluble VEGF receptor-1 (sFlt-1), angiopoietin-2, and microRNA-21 are being investigated to identify which hyperthyroid diabetic patients are at highest risk for DR progression. A risk stratification model incorporating TSH, HbA1c, blood pressure, and baseline OCTA parameters could guide personalized screening intervals. Early trials are evaluating whether combining thyroid-normalizing therapy with selective VEGF inhibition can slow capillary non-perfusion more effectively than either treatment alone. Larger, multinational randomized controlled trials are urgently needed to establish definitive treatment protocols.

A Practical Clinical Approach

For the practicing clinician, the key takeaway is clear: hyperthyroidism is not merely an incidental finding in diabetic patients—it is a potent, modifiable risk factor for worsened retinopathy. A pragmatic approach includes:

  1. Annual TSH screening in all diabetic patients, especially those with any degree of DR. Consider free T₄ if TSH is abnormal.
  2. Prompt endocrinology referral when hyperthyroidism is detected, aiming to achieve euthyroidism over 4–8 weeks with antithyroid medications when possible.
  3. Close coordination between the retina specialist and endocrinologist. Consider more frequent OCTA monitoring during the first 6 months of thyroid treatment, with visits every 4 weeks during the normalization phase.
  4. Patient education about the dual risks: uncontrolled diabetes and unchecked hyperthyroidism synergistically damage vision. Emphasize medication adherence and regular follow-up. Provide written material about symptoms of thyroid dysfunction.
  5. Be aware of drug interactions: antithyroid medications may alter warfarin metabolism (common in hyperthyroid patients with atrial fibrillation), and insulin dose adjustments are often needed. Beta-blockers can be useful to control tachycardia and reduce retinal blood flow acutely.
  6. Consider screening family members of patients with autoimmune thyroid disease, especially if they also have diabetes, as there is a genetic predisposition.

Conclusion

The interplay between hyperthyroidism and accelerated diabetic retinopathy progression represents a clinically significant intersection of endocrinology and ophthalmology. Excess thyroid hormones trigger a cascade of vascular, inflammatory, and angiogenic insults that compound the damage already present from diabetes. By proactively screening for thyroid dysfunction and restoring a euthyroid state, healthcare providers can substantially reduce the burden of diabetic eye disease. Continued research will refine our understanding of the molecular pathways involved, but the evidence already strongly supports integrating thyroid status into standard risk assessment for all diabetic retinopathy patients. The synergistic approach—treating both the hormone imbalance and the metabolic disease—offers the best chance of preserving vision and preventing progression to sight-threatening stages.

For further reading, see the following resources: